Proportion and impact of low positive versus negative estrogen/progesterone receptor status on survival outcomes in HER2-negative breast cancer

Purpose Estrogen receptor low-positive breast cancer (ER-low) is a new entity introduced by the updated American Society of Clinical Oncology/College of American Pathologists guideline. In such tumors ER is expressed in 1–10% of tumor cells. There is limited data available about the biological behavior of this group. This study aims to assess the proportion of ER-low positive breast cancer in a single institute and compare such group with triple negative one as regard clinicopathologic features and survival. Methods This is a retrospective study that included 103 patients diagnosed and treated as breast cancer at National Cancer Institute, Cairo University Cases were categorized according to their hormone receptor status into low ER-positive group (ER/PR expression ≤ 10%) and triple negative group. Tumor characteristics, type of treatment, OS and DFS were evaluated among both groups. Results Triple negative and ER-low positive cases were 79 (76.7%) and 24 (23.3%), respectively. Demographic, clinic-pathologic and treatment characteristics were comparable between both groups. Triple negative group shows higher histologic grade than ER-low positive group (p value = 0.002). According to survival status, there is no significant difference in OS and DFS between triple negative and low ER positive group. In 58 patients receiving neoadjuvant chemotherapy (13 ER-low versus 45 triple negative cases), triple negative group showed higher complete pathologic response when compared to ER-low positive group, despite this difference is not statistically significant (12.7% versus 4.2% respectively, p = 0.513). Conclusion ER-low positive group has the same clinical behavior as triple negative breast cancer.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11543768/v1
Primary Topic
Breast Cancer Treatment Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Proportion and impact of low positive versus negative estrogen/progesterone receptor status on survival outcomes in HER2-negative breast cancer

Marwa A Ahmed, Nancy H Amin, Mohamed Yousri Ahmed, Mostafa A Hussein
Research Square
Breast Cancer Treatment Studies
preprint

Proportion and impact of low positive versus negative estrogen/progesterone receptor status on survival outcomes in HER2-negative breast cancer

Marwa A Ahmed, Nancy H Amin, Mohamed Yousri Ahmed, Mostafa A Hussein
preprint en

Abstract

Purpose Estrogen receptor low-positive breast cancer (ER-low) is a new entity introduced by the updated American Society of Clinical Oncology/College of American Pathologists guideline. In such tumors ER is expressed in 1–10% of tumor cells. There is limited data available about the biological behavior of this group. This study aims to assess the proportion of ER-low positive breast cancer in a single institute and compare such group with triple negative one as regard clinicopathologic features and survival. Methods This is a retrospective study that included 103 patients diagnosed and treated as breast cancer at National Cancer Institute, Cairo University Cases were categorized according to their hormone receptor status into low ER-positive group (ER/PR expression ≤ 10%) and triple negative group. Tumor characteristics, type of treatment, OS and DFS were evaluated among both groups. Results Triple negative and ER-low positive cases were 79 (76.7%) and 24 (23.3%), respectively. Demographic, clinic-pathologic and treatment characteristics were comparable between both groups. Triple negative group shows higher histologic grade than ER-low positive group (p value = 0.002). According to survival status, there is no significant difference in OS and DFS between triple negative and low ER positive group. In 58 patients receiving neoadjuvant chemotherapy (13 ER-low versus 45 triple negative cases), triple negative group showed higher complete pathologic response when compared to ER-low positive group, despite this difference is not statistically significant (12.7% versus 4.2% respectively, p = 0.513). Conclusion ER-low positive group has the same clinical behavior as triple negative breast cancer.

Research Square
Cairo University (EG)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon